Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
Cardiff Oncology, Inc. (CRDF) will release financial results for Q4 and full year 2023 on February 29, 2024. The company focuses on developing cancer therapies using PLK1 inhibition. A conference call and webcast will be held to discuss the results.
02/22/2024 - 08:00 AM
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT -
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29 after the close of trading.
Conference Call and Webcast
Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://cardiffoncology.investorroom.com/events . A replay will be available in the investor relations section on the company's website following the completion of the call.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine Chief Financial Officer 858-952-7670 jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD Gilmartin Group 332-895-3225 Kiki@gilmartinir.com
Media Contact:
Richa Kumari Taft Communications 551-344-5592 richa@taftcommunications.com
When will Cardiff Oncology release financial results for Q4 and full year 2023?
Cardiff Oncology will release financial results for Q4 and full year 2023 on Thursday, February 29, 2024.
What is Cardiff Oncology's focus in developing cancer therapies?
Cardiff Oncology focuses on developing cancer therapies using PLK1 inhibition.
What time is the conference call and webcast scheduled for?
The conference call and webcast are scheduled for 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024.
Where can individuals listen to the live conference call?
Individuals can listen to the live conference call by using the webcast link in the 'Investors' section of Cardiff Oncology's website at https://cardiffoncology.investorroom.com/events.
Will there be a replay available for the conference call?
Yes, a replay will be available in the investor relations section on Cardiff Oncology's website following the completion of the call.
CRDF Rankings
#4132 Ranked by Stock Gains
CRDF Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Services, Medical/Nursing Services, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
San Diego
About CRDF
trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh